These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17620074)

  • 1. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy.
    Savolainen J; Nieminen K; Laaksonen K; Laiho T; Jacobsen L; Lahesmaa R; Terho EO; Valovirta E
    Allergy; 2007 Aug; 62(8):949-53. PubMed ID: 17620074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC.
    Savolainen J; Jacobsen L; Valovirta E
    Allergy; 2006 Oct; 61(10):1184-90. PubMed ID: 16942566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy.
    Laaksonen K; Junikka M; Lahesmaa R; Terho EO; Savolainen J
    J Allergy Clin Immunol; 2003 Dec; 112(6):1171-7. PubMed ID: 14657878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year follow-up study of allergen-induced in vitro cytokine and signalling lymphocytic activation molecule mRNA responses in peripheral blood mononuclear cells of allergic rhinitis patients undergoing specific immunotherapy.
    Nieminen K; Laaksonen K; Savolainen J
    Int Arch Allergy Immunol; 2009; 150(4):370-6. PubMed ID: 19571569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy.
    Savolainen J; Laaksonen K; Rantio-Lehtimäki A; Terho EO
    Clin Exp Allergy; 2004 Mar; 34(3):413-9. PubMed ID: 15005735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy.
    Nieminen K; Valovirta E; Savolainen J
    Pediatr Allergy Immunol; 2010 Feb; 21(1 Pt 2):e174-84. PubMed ID: 19566585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy.
    Guida G; Boita M; Scirelli T; Bommarito L; Heffler E; Badiu I; Bellone G; Mietta S; Mistrello G; Rolla G
    Allergy Asthma Proc; 2012; 33(5):411-5. PubMed ID: 22762741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
    Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
    Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Kopp M; Liebke C; Lange J; Wahn U; Niggemann B
    Int Arch Allergy Immunol; 2005 Feb; 136(2):134-41. PubMed ID: 15650310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.
    Khinchi MS; Poulsen LK; Carat F; André C; Hansen AB; Malling HJ
    Allergy; 2004 Jan; 59(1):45-53. PubMed ID: 14674933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergen induced mRNA expression of interleukin-5, but not of interleukin-4 and interferon-gamma, in peripheral blood mononuclear cells obtained before the pollen season predicts the clinical efficacy of immunotherapy for seasonal allergic rhinitis.
    Kakinoki Y; Ohashi Y; Nakai Y; Washio Y; Nasako Y; Tanaka A; Nakai Y
    Scand J Immunol; 2000 Feb; 51(2):202-8. PubMed ID: 10652165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.
    Bohle B; Kinaciyan T; Gerstmayr M; Radakovics A; Jahn-Schmid B; Ebner C
    J Allergy Clin Immunol; 2007 Sep; 120(3):707-13. PubMed ID: 17681368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cry j 1-induced synthesis of interleukin-5 and interferon-gamma by peripheral blood mononuclear cells of patients with seasonal allergic rhinitis due to Japanese cedar pollens.
    Nakai Y; Ohashi Y; Tanaka A; Kakinoki Y; Washio Y; Masamoto T; Yamada K; Nakai Y; Ohmoto Y
    Acta Otolaryngol Suppl; 1998; 538():143-51. PubMed ID: 9879414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells.
    El Bassam S; Pinsonneault S; Kornfeld H; Ren F; Menezes J; Laberge S
    Immunology; 2006 Jan; 117(1):89-96. PubMed ID: 16423044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro kinetics of allergen- and microbe-induced IL-4 and IFN-gamma mRNA expression in PBMC of pollen-allergic patients.
    Laaksonen K; Waris M; Mäkelä MJ; Terho EO; Savolainen J
    Allergy; 2003 Jan; 58(1):62-6. PubMed ID: 12580809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy.
    Movérare R; Elfman L; Björnsson E; Stålenheim G
    Immunol Lett; 2000 Jul; 73(1):51-6. PubMed ID: 10963811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.